Jazz Pharmaceuticals (JAZZ) Tax Provisions (2012 - 2026)

Jazz Pharmaceuticals' Tax Provisions history runs 15 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• In Q1 2026, Tax Provisions rose 134.27% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at -$248.5 million (down 105.47% YoY), while the FY2025 annual figure was -$272.4 million, down 197.98% from the prior year.
• Tax Provisions for Q1 2026 stood at $6.1 million, up from $5.0 million in the prior quarter.
• The five-year high for Tax Provisions was $11.7 million in Q1 2024, with the low at -$242.4 million in Q3 2025.
• The 5-year median for Tax Provisions is -$17.8 million (2025), against an average of -$37.4 million.
• The sharpest annual moves came in 2023 and 2024: Tax Provisions sank 2958.96% in 2023, then jumped 176.15% in 2024.
• Jazz Pharmaceuticals' Tax Provisions stood at -$100.0 million in 2022, then jumped by 66.91% to -$33.1 million in 2023, then plunged by 75.01% to -$57.9 million in 2024, then jumped by 108.56% to $5.0 million in 2025, then advanced by 23.06% to $6.1 million in 2026.
• Business Quant data shows JAZZ's Tax Provisions at $6.1 million in Q1 2026, $5.0 million in Q4 2025, and -$242.4 million in Q3 2025.